PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN. OKLAHOMA



COMMITTEE ON THE JUDICIARY WASHINGTON, DC 20510-6275

BRUCE A. COHEN, Chief Counsel and Staff Director KOLAN L. DAVIS, Republican Chief Counsel and Staff Director

May 4, 2011

Via Electronic Transmission

Torry Mark Sansone Executive Director American Society of Hypertension, Inc. 148 Madison Avenue New York, NY 10016

Dear Mr. Sansone:

In December 2009, I asked for an accounting of industry funding that American Society of Hypertension, Inc. (ASH) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing. The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ASH's website.

As of the date of this letter, it appears that your organization has taken steps to identify on its website the corporate or industry sponsors and their range of funding support. However, the website does not specify the purposes of that funding. If ASH is currently taking steps to further

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. In particular, please state whether or not ASH will be adding information in the future about the purpose of the funding it receives. If not, please explain why not.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with...physician groups and other prescribers...patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,

Charles E. Grassley Ranking Member

Chuck Gradley

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

Attachment



Committed to Eliminating Hypertension and Its Consequences

ASH BOARD OF DIRECTORS

OFFICER MEMBERS:

Henry R. Black, MD, President
C. Venkata S. Ram, MD, Vice-President
George L. Bakris, MD, President-Elect
Sandra J. Taler, MD, Secretary
Franz H. Messerli., MD, Treasurer
Suzanne Oparl, MD, Immediate Past
President

DIRECTORS-AT-LARGE MEMBERS:

John David Bisognano, MD, PhD
Keith C, Ferdinand, MD
Alan H, Gradman, MD
Daniel T. Lackland, DrPH
Daniel Levy, MD
Robert A, Phillips, MD, PhD
Addison A, Taylor, MD, PhD
William B, White, MD,

EX OFFICIO MEMBERS:

Thomas D Giles, MD, Chairman, ASH Specialists Program Inc.

Michael A Weber, MD, Editor-in-Chief, Journal of Clinical Hypertension (JCH)

Myron H. Weinberger, MD, Editor-in-Chief, Journal of the American Society of Hypertension (JASH)

Torry Mark Sansone, Executive Director

December 21, 2009

The Honorable Senator Charles E. Grassley Committee on Finance Washington, D.C. 20510-6200

Dear Senator Grassley:

In response to the request you submitted to the American Society of Hypertension, Inc. (ASH) as outlined in your December 7, 2009 correspondence, I am providing the financial information requested, see attached file, ASH Revenue From Industry FY 06 through FY09 {Five Worksheets: "Summary FY2006-2009," Revenue from Industry FY2006, Revenue from Industry FY2007, Revenue from Industry FY2008, Revenue from Industry FY2009}.

In response to the five (5) questions you submitted, please note the following:

Question 1: Please describe the policies for accepting industry funding and whether or not ASH allows companies to place restrictions or provide guidance on how funding will be spent.

The Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education (CME) activities.

The Society abides by the ACCME updated Standards for Commercial Support. In addition, the Society accepts, upholds and endorses the related guidelines of the American Medical Association (AMA), the Pharmaceutical Manufacturers Association (PhRMA), the Accreditation Council for Continuing Medical Education (ACCME) and the Office of the Inspector General (OIG).

. . .



Committed to Eliminating Hypertension and Its Consequences

The Society accepts funding from industry according to the ACCME Standards for Commercial Support, and in compliance with the guidelines of the organizations listed above. The Society accepts funding only under the terms, conditions, and specifications of the Society, and does not allow outside companies to place restrictions or to provide guidance on how funding will be spent.

Further, the Society has developed a guideline specifically describing the Society policies for industry funding, "American Society of Hypertension, Inc. (ASH) – Policy for Outside Source Funding." See attached file: ASH Policy for Outside Source Funding.

Question 2: If ASH allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.

The Society does not allow companies to place restrictions on industry funding. Please see response to Question 1.

Question 3: Please explain what policies, if any, that ASH plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

The Society's Disclosure procedures and forms underwent a comprehensive review in 2005-2006. As a result, in summer 2006, new protocol, guidelines, and forms were established and implemented. These are periodically reviewed by the Board and other Society committees, and new forms were implemented after the September 2009 Board Meeting.

The Society's policy is to disclose all funding in relation to the activity or program for which the funding was granted. The Society believes that its protocol ensures transparency of funding.



Committed to Eliminating Hypertension and Its Consequences

Question 4: Please explain your policies on disclosure of outside income by your top executives and board members.

The Society's Disclosure policy and forms underwent a comprehensive review in 2005-2006. As a result, in Summer 2006, new protocol, guidelines, and forms were established and implemented.

All Board Members and top executives are required to disclose outside income and other financial relationships by submitting an annual "Disclosure Form for Responsible Persons." Disclosure forms are filed for the previous calendar year.

The ASH Disclosure Policy and form are periodically reviewed by the Board and other Society Committees, and new forms were implemented in September 2009. The policy and forms have been linked to the ASH website.

Question 5: Please provide the disclosures of outside income filed with your organization by your top executives and board members.

See attached files with Disclosure Forms for ASH Responsible Persons for 2006, 2007, and 200: Calendar Year 2006 Disclosures.pdf, Calendar Year 2007 Disclosures.pdf, Calendar Year 2008 Disclosures.pdf. In accord with Society protocol, ASH Disclosure Forms for 2009 are not submitted by ASH Responsible Persons until 2010.

Sincerely,

Torry Mark Sansone Executive Director

Toesgrack Dansone

REVENUE FROM INDUSTRY SUMMARY 2006-2009

	2006	2007	2008	2009
ANNUAL SCIENTIFIC MEETING	\$508,350.00	\$489,985.00	\$635,104.00	\$346,525.00
CORPORATE DUES	\$262,000.00	\$165,000.00	\$250,000.00	\$150,000.00
EDUCATIONAL SERVICES	\$3,373,334.56	\$3,189,305.48	\$3,256,846.40	\$4,004,509.00
DONATION	\$1,000.00	\$1,100.00	\$7,000	\$3,250.00
TOTAL	\$4,144,684.56	\$3,845,390.48	\$4,148,950.40	\$4,504,284.00

TOTAL REVENUE RECEIVED FROM PHARMA FY 2006

	01	4,144,684.56	TOTAL
		1,000,00	SOB LOTAL
		1,000,00	SUB TOTAL
DONATION	O FOREST	1,000,00	
			DONATIONS
and the state of t	5	3,373,334.56	SUB TOTAL
STATEGORIA	BI	20.550 51	
Componie	310 330 30 301300	210 277 217	
SYMPOSIUM	160 636 00 BOHRBINGED INGE HEIM	20 25 20 25	
TOUR DOES HE WAS A STATE OF THE	DESCRIPTION AND ADDRESS OF THE PARTY OF THE	176 000 00	
ENDORING MAJERUAL	EA DOO OO SEIZER AVIIM	20,000,00	
ENCORTING PIA CENAL	ADBOTT OF	10,000,00	
BRIDING MATERIAL	TO DOD OU SCHWARTS	10,000,00	
TOU OFFICE AND THE PROPERTY OF	COORDINATED INCOMPENS	10 000 00	
ENDURING MATERIAL	DISTORDING INGREDITATION	JO 367 551	
TATOLOGICA	BRANCI	14 006 22	
SANDOSTIM	SANEYO	36 800 00	
MUISORWYS	OMBON	78 170 00	
SYMPOSIUM	GLAZOSMITHKLINE	65,992 15	
SYMPOSIUM	SANOFI	73,533.36	
SYMPOSIUM	ABBOTT LABS- MEDIMEDIA	56,382.91	
SYMPOSIUM	ASTRAZENECA- INNOVIA	81,140.73	
MUISDAMYS	MERCK	48,469.00	
SYMPOSIUM	FOREST-ADVANTAGE COMMUNICATIONS	76,800.00	
SYMPOSIUM	74,865.08 PFIZER - ACADEMY FOR HEALTH CARE EDU SYMPOSIUM	74,865.08	
A THE PROPERTY OF THE PROPERTY			
SYMPOSIUM. SPECIAL POPULATION SEMINARS (AFRICAN AMERICAN ASIAN HISPANIC	338 876 00 MERCK	338,876,00	
SYMPOSIUM		215 243 00	
MNISORMAS		247 800 00	
SYMPOSIUM		204.987.00	
SYMPOSIUM		243,001,00	
SYMPOSIUM		274,429.00	
SYMPOSIUM		323,600.00	
		ES:	EDUCATIONAL SERVICES:
	0	262,000.00	SUB TOTAL
CORP DUES	SERVIER	15,000,00	
CORP DUES	SANKYO	15,000.00	
CORP DUES	0 PFIZER	15,000.00	
CORP DUES	15,000.00 NOVARTIS	15,000.00	1
CORP DUES AND EXHIBIT FEE	MERCK	97,000.00	J
CORP DUES	15,000.00 GLAXOSMITHKLINE	15,000.00	
CORP DUES		15,000.00	79.1
CORP DUES	15,000.00 BRISTOL MYERS SQUIBE	15,000.00	
CORP DUES		15,000.00	
CORP DUES		15,000.00	
CORP DUES		15,000.00	1
CORP DUES	15,000.00 ABBOTT	15,000.00	
			CORPORATE DUES
	0	508,350.00	SUB TOTAL
FACULTY ACKNOWLEDGEMENT/RECOGNITION EVENT	NOVARTIS	65,000.00	
LANYARDS	PRIZER - CLINE DAVIS	30,000,00	
REGISTRATION BAG	SANOFI-AVENTIS	40,000.00	
PROGRAM BOOK	NOVARTIS	65,000.00	
HOTEL KEYS	NOVARTIS: ADVANTAGE COMMUNICATIONS	5,000.00	
JOURNAL PUBLICATION OF SCIENTIFIC ABSTRACTS	GLAXOSMITHKLINE	30,000,00	
PHANNA, CYT THERAFELTICS, MICROLIFE, EXHIBITS 0.00 SANDET AVENTIS, VASAMED EXHIBITS	PHARMA, CVT THERAPEUTICS, MICROLIFE, SANDEI AVENTIS, VASAMED	273,350.00	
	INTEGRIUM, OMRON, LE,M. SANKYO		
	SPACE LABS MEDICALS, MEDIA ALERTS,		
	DIAGNOSTICS, BMS, TIBA MEDICAL,		
	INTERNATIONAL HYPERTENSION		
	RELIANT, PFIZER, QUEST DIAGNOSTICS,		
	KENT SCIENIFIC, NATURE AMERICA,		
	KIDNEY FOUNDATION, HUMANA PRESS,		
	W.A.BAUM, ABBOTT LABS, RESPIRONICS, MYOGEN, WYETH, NOVARTIS, NATIONAL		
	SCACK, MERGK, LYNCH, ASTRAZENECA,		
		EETING	ANNUAL SCIENTIFIC MEETING
	The second secon		
COMMENTS	INDUSTRY	RECEIVED INDUSTRY	

			7	
### TOTAL GRANT AMOUNT INDUSTRY AMOUNT INDUSTRY Company Co				
ENTIFIC MEETING \$15,000.00 BI KENT INTEGRUM, SLACK INC, WA BANK, DALICHI SANKYO, ATCOR HENT, MALICHI SANKYO, ATCOR HENT, MALICHI SANKYO, ATCOR HENT, MALICHI SANKYO, ATCOR HENDICAL, INTEGRUM, SLACK INC, WA HENCA, LINEGURE, MATUNATION, MONARTIS, HOMEDICAL, INTEGRUR, MEDICAL, MATUNATION, MALICHI SANKYO, ATCOR HEDICAL, INTEGRUR, MEDICAL, MATUNATION, MEDICAL, INTEGRUR, MEDICAL, MED		TOTAL GRANT AMOUNT	INDUSTRY	COMMENTS
### CENT_INTEGRUM, SLACK INC. WA BALM, DATICH! SANKYO, ATCOR BENTALE, MICROLIFE, BI, MATURE, HOMEDICA, LIMBORATION, CARDIDOYNAMIC, HOMEDICA, LIMBORATION, CARDIDOYNAMICS BIOMATE CORP. SPACELASS MEDICAL, SES, 2000.00 MOVARTIS ### SIS, 2000.00 MOVARTIS ### SIS, 2000.0	ANNUAL SCIENTIFIC MEETI			
RENT, INTEGRUM, SLACK INC, WA RENT, INTEGRUM, SLACK INC, WA RAIN, DAILTH, SANYO, ATOCA, RAIN, DAILTH, RAIN, RAIN		\$15,000.0	18	SCIENTIFIC AWARDS
MEDICAL, INTECURE, NATIONAL MEDICAL, INTECURE, NATIONAL MEDICAL, INTECURE, AUTOMAL MEDICAL, INTERNATIONAL MEDICAL, INTERNATIONAL MEDICAL, INTERNATIONAL MEDICAL, MISS, PIEZER, MICROLITE, BILL, NATURE PROJECT, MICROLITE, MICROLITE, MICROLITE, BILL, NATURE PROJECT, BILL, NATURE PROJECT, MICROLITE, BILL, NATURE PROJECT, BILL, NATURE PROJECT, MICROLITE, BILL, NATURE PROJECT, BILL, NATURE PROJECT, MICROLITE, BILL, NATURE PROJECT, M		00.000,616	KENT, INTEGRIUM, SLACK INC, WA BAUM. DAIICHI SANKYO. ATCOR	SCIENTIFIC AWARDS
### PRIZER, MICROLIFE, BI, NATURE ####################################			MEDICAL, ITAMAR MEDICAL, BMS,	
MICHAHON, CARDIDOWANTIS MICHAHON, CARDIDOWANTIS MICHAHOTONAL, HESPERION, LIPPINCOTT WILLIAMS MEDICAL, LIPPINCOTT WILLIAMS MILTONS, SAD,000,00 BORHATIS SAD,000,00 BORHATIS SAD,000,00 BORHATIS SAD,000,00 BORHATIS SAS,000,00 BO			PFIZER, MICROLIFE, BJ, NATURE AMERICA, A&D ENGINEERING, HOMEDICS USA, MICRO MEDICAL, CVRX, DIASORIN, KING, HEMOCUE,	
\$52,000.00 CHERKING FILLION, PUL. \$53,000.00 SOEHRINGER INGELHEIM \$40,000.00 SOEHRINGER INGELHEIM \$40,000.00 SOEHRINGER INGELHEIM \$45,000.00 SOENOFEL \$45,000.00 SOENOFEL \$15,000.00 SOE			INTERNATIONAL, HESPERION, BIOMATE CORP, SPACELABS MEDICAL, LIPPINCOTT WILLIAMS & WILKINS, COSERVEIO WILLIAMS & WILKINS,	
\$40,000.00 ENDIFICINGENTION \$40,000.00 SANDIA \$450,000.00 SANDIA \$450,000.00 SANDIA \$55,000.00 NOVARTIS \$55,000.00 NERCK \$55,000.00 NERCK \$15,000.00 SATRAZENCA \$15,000.00 SATRAZENCA \$15,000.00 SATRAZENCA \$15,000.00 FIZER \$15,000.00 FIZER \$15,000.00 SANNYO \$15,000.00 SANNYO \$15,000.00 SANNYO \$150,000.00 SANNOFI \$237,025.00 NOVARTIS \$237,025.00 NOVARTIS \$237,025.00 NOVARTIS \$237,025.00 NOVARTIS \$35,000.00 SANDITI-KALINE \$237,025.00 NOVARTIS \$35,000.00 FOREST \$35,000.00 FOREST \$35,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$35,000.00 FOREST \$31,000.00 FOREST		\$65,000.00	NOVARITS	ROGRAM
\$65,000.00 NOVARTIS \$55,000.00 NERCK \$15,000.00 NERCK \$15,000.00 NERTHINGER INGELLEHIM \$15,000.00 NOVARTIS \$172,300.00 NOVARTIS \$172		\$30,000.00	SANOFI SANOFI	REGISTRATION BAGS
\$489,985.00 \$489,985.00 \$15,000.00 ABOTT \$15,000.00 ASTRAZRICA \$15,000.00 BASTROLMYERS SQUIBB \$15,000.00 FOREST \$172,300.00 FOREST \$172,300.00 FOREST \$172,300.00 FOREST \$387,925.00 FOREST \$387,925.00 FOREST \$387,925.00 FOREST \$387,000.00 FOREST \$387,000.00 FOREST \$383,70.00 FOREST \$383,70.00 FOREST \$383,70.00 FOREST \$35,000.00 FOREST \$15,000.00 FOREST		\$65,000.00	NOVARTIS	FACULTY ACKNOWLEDGEMENT/RECOGNITION
\$489,985.00 \$15,000.00 ABBOTT \$15,000.00 ASTRAZENCA \$15,000.00 BOEHRINGER INGELEHIM \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$112,300.00 DAILCHI AND FOREST \$220,400.00 KING PHARMA \$224,900.00 BILEAD \$82,400.00 KING PHARMA \$224,900.00 MOVARTIS \$237,000.00 MOVARTIS \$237,000.00 MOVARTIS \$237,000.00 SERVIER \$237,000.00 MOVARTIS \$237,000.00 SERVIER \$237,000.00 MOVARTIS \$35,500.00 SERVIER \$237,000.00 MOVARTIS \$35,500.00 SERVIER \$237,000.00 MOVARTIS \$35,500.00 MOVARTIS \$35,500.00 MOVARTIS \$35,500.00 SERVIER \$35,000.00 SERVIER \$35,000.00 SERVIER \$36,000.00 SERVIER \$36,000.00 SERVIER \$36,000.00 SERVIER \$36,000.00 SERVIER \$31,000.00 SERVIER \$		\$5,000.00	MERCK	SPECIAL SEMINAR AFRICAN AMERICANS
\$15,000.00 ABOUTT \$15,000.00 ASTRAZENCA \$15,000.00 BATSTOL MYERS SQUIBB \$15,000.00 FOREST \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$172,300.00 MOVARTIS \$274,102.00 KING PHARMA \$224,102.00 KING PHARMA \$234,102.00 KING PHARMA \$234,102.00 MING PHARMA \$234,102.00 MING PHARMA \$234,000.00 MERCK \$83,471.00 SANUM \$237,000.00 MERCK \$83,471.00 SANUM \$6,000.00 MATUM \$1,100.00 FOREST ABBOTT \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT	SUB TOTAL	\$489,985.00		
\$15,000.00 ABOTT \$15,000.00 BOCHRINGER INGELEHIM \$15,000.00 BOCHRINGER INGELEHIM \$15,000.00 BOCHRINGER SQUIB6 \$15,000.00 GRISTOL WYERS SQUIB6 \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 PEIZER \$15,000.00 DAITCHI AND FOREST \$224,020.00 KOVARTIS \$127,000.00 MOVARTIS \$137,000.00 MOVARTIS \$1,000.00 MOVARTIS \$1,00	CORPORATE DUES			
\$15,000.00 ASTRAZENCA \$15,000.00 BRISTOL MYERS SQUIBB \$15,000.00 BRISTOL MYERS SQUIBB \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 SANKYO \$15,000.00 SANKYO \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 FOREST \$172,300.00 DAIICHI AND FOREST \$172,300.00 PRIZER \$124,930.00 PRIZER \$124,930.00 FOREST \$15,000.00 FOREST \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$15,000.00 BRISTOL MYERS SQUIBB \$15,000.00 FOREST \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 SERVIER \$123,000.00 DAILCHI AND FOREST \$287,025.00 NOVARTIS \$1237,025.00 NOVARTIS \$224,029.00 SILCHI AND FOREST \$237,025.00 NOVARTIS \$85,160.00 GILEAD \$85,160.00 GILEAD \$85,160.00 GILEAD \$85,160.00 SANOFI - QED \$85,160.00 SANOFI - QED \$85,160.00 SANOFI - QED \$81,371.00 SANOFI - QED \$1,200.00 FOREST \$1,000.00 DAILCHI \$1,000.00 FOREST \$1,000.00 DAILCHI \$1,000.00 FOREST \$1,000.00 DAILCHI \$1,000.00 FOREST \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$15,000.00 FOREST \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 MERCK \$15,000.00 PETZER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$127,000.00 DAILCHI AND FOREST \$234,023.00 INOVARTIS \$224,023.00 INOVARTIS \$224,023.00 INOVARTIS \$237,025.00 INOVARTIS \$237,025.00 INOVARTIS \$237,025.00 INOVARTIS \$237,025.00 INOVARTIS \$237,000.00 MERCK \$337,000.00 MERCK \$337,000.00 MERCK \$337,000.00 SANOFI - QED \$35,066.81 SINSTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 DAILCHI \$4,000.00 POTZER \$32,000.00 DAILCHI \$4,000.00 POTZER \$33,450.00 POTZER \$3		\$15,000.00		CORP DUES
\$15,000.00 MERCK \$15,000.00 NOVARTIS \$15,000.00 PETZER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 DAILCHI AND FOREST \$234,030.00 INOVARTIS \$234,030.00 INOVARTIS \$234,039.00 BI \$234,039.00 BI \$237,035.00 NOVARTIS \$353,160.00 FIZER \$327,000.00 MERCK \$83,271,00 SANOFI - QED \$85,865.92 FOREST \$43,260.71 GLAOSMITHKLINE \$53,460.71 GLAOSMITHKLINE \$54,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 AXIUM \$5,000.00 DAILCHI \$6,000.00 DAILCHI \$6,000.00 DAILCHI \$6,000.00 DAILCHI \$6,000.00 DAILCHI \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$15,000.00 NOVARTIS \$15,000.00 PFIZER \$15,000.00 PFIZER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$270,430.00 NOVARTIS \$172,300.00 PFIZER \$224,102.00 NOVARTIS \$224,102.00 NOVARTIS \$224,102.00 NOVARTIS \$224,2939.00 BI \$227,035.00 NOVARTIS \$237,035.00 NOVARTIS \$237,035.00 NOVARTIS \$327,035.00 NOVARTIS \$327,035.00 NOVARTIS \$327,035.00 MERCK \$3371,000.00 MERCK \$3371,000.00 MERCK \$3371,000.00 FOREST \$3371,000.00 FOREST \$3571,000.00 PFIZER \$30,666.85 BRISTOL MYERS SQUIBB MS-SANOFI \$410,000.00 DAIICHI \$45,000.00 DAIICHI \$45,000.00 AXIUM \$45,000.00 DAIICHI \$45,000.00 DAIICHI \$53,189,305.48 \$31,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$15,000.00 PFIZER \$15,000.00 SERVIER \$15,000.00 SERVIER \$15,000.00 SERVIER \$172,300.00 NOVARTIS \$172,300.00 PFIZER \$172,300.00 PFIZER \$172,300.00 MERCK \$1527,000.00 MERCK \$1527,000.00 MERCK \$1527,000.00 MERCK \$15371,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$150,000.00 FOREST \$100,000.00 PFIZER \$150,000.00 PFIZER \$150,000.00 PFIZER \$15,000.00 PFIZER \$15,000.00 DAIICHI \$14,000.00 PFIZER \$15,000.00 DAIICHI \$15,000.00 DAIICHI \$14,000.00 PFIZER \$15,000.00 DAIICHI \$11,000.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$15,000.00 SERVIER \$120,0430.00 NOVARTIS \$127,0430.00 NOVARTIS \$127,0300.00 DAILCHI AND FOREST \$224,102.00 KING PHARMA \$224,939.00 BI \$237,095.00 NOVARTIS \$85,85.92 FOREST \$35,471.00 SANOFI QED \$85,865.92 FOREST \$31,000.00 BARCK \$83,471.00 SANOFI QED \$74,060.71 GLAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB MS-SANOFI \$15,000.00 BRISTOL MYERS SQUIBB MS-SANOFI \$15,000.00 DAILCHI \$60,000.00 DAILCHI \$60,000.00 DAILCHI \$60,000.00 DAILCHI \$60,000.00 DAILCHI \$60,000.00 DAILCHI \$60,000.00 DAILCHI \$51,000.00 DAILCHI \$51,000.00 DAILCHI \$51,000.00 DAILCHI \$51,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$15,000.00		CORP DUES
\$155,000.00 WOVARTIS \$1270,430.00 NOVARTIS \$1172,300.00 DATICHI AND FÖREST \$287,925.00 PFIZER \$224,000.00 BIS \$224,000.00 BIS \$224,000.00 BIS \$227,095.00 NOVARTIS \$257,095.00 NOVARTIS \$257,000.00 BIS \$257,000.00 BIS \$274,000.71 GLAXOSMITHKLINE \$20,000.00 BRISTOL MYERS SQUIBB \$20,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$60,000.00 AXIUM \$6,000.00 PFIZER \$93,490.00 PFIZER \$93,500.00 DATICHI \$3,189,305.48		\$15,000.00		CORP DUES
44. SERVICES: \$270,430.00 NOVARTIS \$172,300.00 DAILCHI AND FOREST \$397,925.00 PFIZER \$224,939.00 BI \$237,995.00 NOVARTIS \$85,160.00 GILEAD \$85,160.00 MERCK \$83,471.00 SANOFI - QED \$74,060.71 GLAXOSWITH-KLINE \$94,660.81 BRISTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 FOREST \$15,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 AXIUM \$149,000.00 PFIZER \$93,450.00 DAIICHI \$150,000.00 DAIICHI \$11,000.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT	SUB TOTAL	\$165,000.00		
44. SERVICES: \$172,300.00 NOVARTIS \$172,300.00 PAITCHI AND FOREST \$187,235.00 PHIZER \$234,023.00 KING PHARMA \$234,939.00 BI \$224,023.00 NOVARTIS \$237,095.00 NOVARTIS \$523,093.00 MERCK \$53,100.00 MERCK \$63,471.00 SANDFI QED \$63,8471.00 SANDFI QED \$74,060.71 GLAXOSMITHKLINE \$29,666.85 BRISTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 DAIICHI \$410,000.00 PHIZER \$59,000.00 AXIUM \$4,000.00 PHIZER \$99,500.00 DAIICHI \$59,500.00 DAIICHI \$51,000.00 PHIZER \$99,500.00 DAIICHI \$51,000.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT				
\$220,430.00 POREST \$387,925.00 PFIZER \$387,925.00 PFIZER \$327,925.00 KING PHARMA \$224,102.00 KING PHARMA \$224,939.00 BI \$223,000.00 GILEAD \$85,160.00 GILEAD \$85,865.92 FOREST \$83,71,000.00 MERCK \$83,471.00 SANORTI QED \$74,060.71 GIAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB MS-SANOFI \$15,000.00 BRISTOL MYERS SQUIBB MS-SANOFI \$15,000.00 DAIICHI \$6,000.00 DAIICHI \$6,000.00 AXIUM \$149,000.00 PFIZER \$99,500.00 DAIICHI \$37,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT	EDUCATIONAL SERVICES:			
\$397,925.00 PFIZER \$224,102.00 KING PHARMA \$224,939.00 BI \$237,095.00 NOVARTIS \$85,160.00 GILEAD \$85,865.92 FOREST \$337,000.00 MERCK \$83,471.00 SANDET \$337,000.00 MERCK \$63,471.00 SANDET \$32,000.00 FOREST \$15,000.00 BRISTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 BRISTOL MYERS SQUIBB MS-SANDEI \$10,000.00 POREST \$30,200.00 DAIICHI SANKYO \$20,000.00 AXIUM \$6,000.00 AXIUM \$149,000.00 PFIZER \$99,500.00 DAIICHI \$37,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$172,300.00	DAIICHI AND FOREST	SYMPOSIUM
\$224,030.00 KING PHARMA \$224,930.00 Bt \$237,095.00 NOVARTIS \$85,160.00 GILEAD \$85,865.92 FOREST \$331,000.00 MERCK \$83,471.00 SANOFI - QED \$74,060.71 GLAXOSNITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 FOREST \$15,000.00 FOREST \$30,000.00 FOREST \$302,340.00 DAIICHI SANKYO \$20,000.00 AXIUM \$6,000.00 AXIUM \$149,000.00 PFIZER \$93,450.00 DAIICHI \$37,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$387,925.00		2 SYMPOSIA
\$237,095.00 GILEAD \$85,160.00 GILEAD \$85,865.92 FOREST \$83,1471.00 SANOFI - QED \$33,471.00 SANOFI - QED \$34,060.71 GLAXOSNITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB \$25,000.00 FOREST \$15,000.00 BAISTOL MYERS SQUIBB MS-SANOFI - \$10,000.00 DAIICHI SANKYO \$20,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 PRIZER \$93,450.00 DAIICHI \$99,500.00 DAIICHI \$33,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT \$1,000.00 FOREST, ABBOTT		\$224,102.00	1RMA	SYMPOSIUM
\$85,160.00 GILEAD \$85,865.92 FOREST \$371,000.00 MERCK \$83,471.00 SANOFI QED \$74,060.71 GLAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB MS-SANOFI \$15,000.00 BRISTOL MYERS SQUIBB MS-SANOFI \$100,060.00 DAIICHI \$15,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 PAIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$149,000.00 PRIZER \$93,450.00 PRIZER \$149,000.00 PRIZER \$140,000 PRIZER \$140,000 PRIZER \$140,000 PRIZER		\$237,095,00	S	SYMPOSIUM
\$85,865.92 FOREST \$83,471.00 SANOFT QED \$83,4050.71 SANOFT QED \$74,060.71 GLAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB \$25,000.00 BRISTOL MYERS SQUIBB MS-SANOFT \$15,000.00 FOREST \$4100,000.00 FOREST \$60,000.00 AXIUM \$6,000.00 PRIZER \$6,000.00 PRIZER \$93,450.00 PRIZER \$99,500.00 DAIICHI \$3,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00 FOREST, ABBOTT		\$85,160,00		SYMPOSIUM
\$83,471.00 SANOFI QED \$83,471.00 SANOFI QED \$74,060.71 GLAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB \$25,000.00 PROEST \$15,000.00 PROEST \$20,000.00 PAICHI SANKYO \$6,000.00 AXIUM \$6,000.00 PAICHI \$60,000.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,500.00 DAIICHI \$3,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00		\$85,865,92		SYMPOSIUM AND ENDIBING MATERIAL
\$74,060.71 GLAXOSMITHKLINE \$80,666.85 BRISTOL MYERS SQUIBB MS-SANOFI AV \$15,000.00 FOREST \$15,000.00 BRISTOL MYERS SQUIBB MS-SANOFI AV \$100,000.00 BAITCHI \$40,000.00 BAITCHI \$50,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,500.00 BAITCHI \$3,189,305.48 \$1,100.00 FOREST, ABBOTT		\$83,471,00		SYMPOSIUM AND ENDORING MATERIAL
\$80,566,459 RK37 OL MYERS SQUIBB MS-SANOFI AX \$100,000.00 BRISTOL MYERS SQUIBB MS-SANOFI AX \$100,000.00 BRISTOL MYERS SQUIBB MS-SANOFI AX \$100,000.00 BRISTOL MYERS SQUIBB MS-SANOFI AX \$20,000.00 BRISTOL MY \$6,000.00 BRISTOL MY \$6,000.00 BRISTR \$5149,000.00 PFIZER \$93,450.00 BRISTR \$99,500.00 BAIICHI \$3,189,305.48		\$74,060.71	GLAXOSMITHKLINE	SYMPOSIUM
\$15,000,00 BRISTOL MYERS SQUIBB MS-SANOFI AV \$100,000.00 DAIICH! SANKYO \$20,000.00 FOREST \$362,240.00 DAIICH! \$6,000.00 AXIUM \$6,000.00 JAXIUM \$6,000.00 FOREST \$149,000.00 FFIZER \$93,450.00 BRIZER \$99,500.00 DAIICH! \$3,189,305.48		\$25,000.00	FOREST	REVIEW COURSE
\$10,000.00 [AAICH] \$20,000.00 FOREST \$362,240.00 DAICH] \$6,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 AXIUM \$149,000.00 FIZZER \$93,450.00 FIZZER \$99,500.00 FIZZER \$99,500.00 DAIICH] \$3,189,305.48		\$15,000.00	BRISTOL MYERS SQUIBB MS-SANOFI AV	REVIEW COURSE
\$20,200.00 FOREST, ABBOTT \$1,100.00 \$1,100.00		\$100,000.00	DAIICHI SANKYO	REVIEW COURSE
\$6,000.00 AXIUM \$6,000.00 AXIUM \$6,000.00 AXIUM \$149,000.00 PRIZER \$93,450.00 PRIZER \$93,450.00 PRIZER \$93,450.48 \$3,189,305.48 \$1,100.00 FOREST, ABBOTT		\$362,340.00	DAIICHI	SYMPOSIUM AND ENDURING MATERIAL
\$5,000.00 AXIUM \$5,000.00 AXIUM \$149,000.00 PRIZER \$93,450.00 PRIZER \$99,500.00 DATICHT \$3,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00		\$6,000.00		SYMPOSIUM
\$149,000.00 PAIZER \$19,000.00 PAIZER \$93,450.00 PAIZER \$99,500.00 DATICHT \$3,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00		\$6,000.00		SYMPOSIUM
\$93.450.00 PFIZER \$99.500.00 DATICHI \$3,189,305.48 \$1,100.00 FOREST, ABBOTT \$1,100.00		\$6,000.00		SYMPOSIUM
\$3,189,305.48 \$3,189,305.48 \$1,100.00 FOREST, ABBOTT		\$93,450,00		SYMPOSIUM
\$1,100.00 FOREST, ABBOTT	WALL BILL	599,500.00		MUISOMMYS
\$1,100.00 FOREST, ABBOTT \$1,100.00	SUB TOTAL	\$3,189,305.48		
\$1,100.00 FOREST, ABBOTT \$1,100.00	DONATIONS			
\$1,100,000		\$1,100.00	FOREST	DONATION
	200			
	SUB TOTAL	\$1,100,00		

TOTAL REVENUE RECEIVED FROM PHARMA FY 2008

	TOTAL GRANT	INDUSTRY	COMMENTS
ANNUAL SCIENTIFIC MEETING		The Court August 1	
		BI, BMS, SANOFI AVENTIS, CVRx, DAIICHI, GSK, MERCK, NICOX, NOVARTIS, PFIZER I,	
	\$38,000.00	BOEHRINGER INGELHEIM	HOTEL KEYS & LANYARDS
	\$65,000.00	NOVARTIS	PROGRAM BOOK
	\$40,000.00	\$40,000.00 SANOFI-AVENTIS	REGISTRATION BAG SPONSORSHIP
	\$35,000.00	FOREST	SPECIAL SEMINAR PRIMARY CARE PHYSICIANS
	\$50,000.00	FOREST	PATIENT HEALTH SCREENING AND EDUCATION PROGRAM
	\$35,000.00	NOVARTIS	PATIENT HEALTH SCREENING AND EDUCATION PROGRAM
SUB TOTAL	\$635,104.00		
CORPORATE DUES			
	\$15,000.00	ASTRAZENCA	CORP DUES
	\$15,000.00	BOEHRINGER IN	CORP DUES
	\$15,000.00	BRISTOL MYERS SQUIBB	CORPOUES
	\$15,000.00	\$15,000.00 GLAXOSMITHKLINE	CORP DUES
	\$15,000.00	MERCK	CORP DUES
	\$15,000.00	PFIZER	CORP DUES
	\$15,000.00	SANKYO	CORP DUES
	\$50,000.00 TAKEDA	TAKEDA	NEW CORP MEMBER
SUB TOTAL	\$250,000.00		
EDUCATIONAL SERVICES:			
	73,700.00	GLAXOSMITHKLINE	SYMPOSIUM
	\$80,000.00	NICOX	SYMPOISIUM AND CORP DUES
	281,349.65	NOVARTIS	SYMPOSIUM
	394,880.00	MERCK	SYMPOSIUM AND ENDURING MATERIAL
	81,565.00	FOREST-ADVANTAGE	SYMPOSIUM
	\$500,000.00	PEIZER	ENDURING MATERIAL
	\$713,650.00	DALICHI SANKYO	ENDURING MATERIAL
	10,000.00	GLAXOSMITHKLINE- PROCOM	ENDURING MATERIAL
	12,000.00	DALICHI SANKYO	ENDURING MATERIAL
	264,430.00	FOREST	SYMPOSIUM
	99;500.00 DATICHT	DATICHI - SCIUS	SYMPOSIUM
	\$12,000.00	NICOX- S	SYMPOSIUM
SUR TOTAL	\$18,140.00	SWB	SYMPOSIUM
100	o constant		
DONATIONS			
	\$7,000.00	FOREST	DCNA
SUB TOTAL	\$7,000.00		
TOTAL	\$4,148,950.40		

	TOTAL GRANT	COMMENTS
	BI, BMS, SANOFI AVENTIS, CVRX, DAIICHI,GSK, MERCK, NICOX, NOVARTIS, PFIZER I, FOREST,	
NAME OF PERSONS ASSESSED.	TOD, JE JOO COMMENT TO THE PARTY OF THE PART	
	8,000.00 BOEHRINGER INGELHEIM	
	65,000,00 NOVARTIS	PROGRAM BOOK
	40,000.00 SANOFI-AVENTIS	REGISTRATION BAG
	60,000.00 DAIICHI SANKYO	FACULTY ACKNOWLEDGEMENT/RECOG
SUBTOTAL	346,525.00	
CORPORATE DUES		
	15,000.00 BOEHRINGER INGELHEIM	
	15,000.00 FORES!	CORP DUES
	15,000.00 MERCK	CORP DUES
	15,000.00 NOVARTIS	CORP DUES
	15,000.00 PFIZER	CORP DUES
	15,000.00 GILEAD	CORP DUES
	15,000,00 NICOX	CORP DUES
	15,000.00 DAIICHI SANKYO	CORP DUES
SUB TOTAL	150,000.00	
EDUCATIONAL SERVICES:		
	253,510.00 FOREST	SYMPOSIUM
	196,941.00 CALPIS	SYMPOSIUM
	781,390.00 DAIICHI	SYMPOSIUM AND REGISTRATION FEE
	162,109.00 NICOX	SYMPOSIUM
	240,000,00 DAIICHI SANKYO	REGISTRATION FEES
	DAIICHI	REGISTRATION FEES
	24,000,00 PFIZER-AXIUM	ENDURING MATERIAL
	22,617.00 GLAXOSMITHKLINE	ENDURING MATERIAL
	161 900.00 DAIICHI SANKYO	ENDURING MATERIAL
	10,000,00 HAVAVISION	ENDURING MATERIAL
		SYMPOSIUM
SUB TOTAL	509.00	
DONATIONS		
	3,250.00 FOREST	DONATION
SUB TOTAL	3,250.00	
TOTAL	4.504.284.00	